NanoMosaic Taps Neurology Star to Lead Diagnostic Revolution

BOSTON, MA – January 06, 2026 – Diagnostics firm NanoMosaic has appointed Dr. Anne Marie Morse, an internationally recognized neurologist and sleep medicine specialist, to chair its new Clinical Advisory Board, a strategic move signaling a major push to overhaul how neurological diseases are diagnosed, monitored, and treated. The appointment aims to accelerate the integration of the company's ultra-sensitive Tessie™ diagnostic platform into pharmaceutical development and clinical practice, potentially transforming the fields of companion diagnostics and "Brain Health."

This initiative brings together visionary clinical leadership with next-generation technology to tackle one of medicine's most challenging areas. With high failure rates and staggering costs plaguing neurological drug development, the industry is in desperate need of tools that can identify the right patients for the right therapies earlier and more accurately. NanoMosaic is betting that Dr. Morse's guidance and its unique platform are the answer.

A Visionary Leader for a New Diagnostic Era

Dr. Anne Marie Morse is not a typical board appointee. Her career is a testament to a relentless drive for patient-centered innovation that spans clinical practice, academic research, and digital health transformation. As the Director of Child Neurology and Pediatric Sleep Medicine at Geisinger, she has been at the forefront of expanding access to care, growing her department from five to fifteen providers since 2018 and founding the institution's child neurology residency program.

A respected key opinion leader in sleep medicine, particularly in disorders like narcolepsy, Dr. Morse has championed the use of technology to improve patient outcomes. She was instrumental in digital transformation initiatives at Geisinger, where over half of neurology and sleep visits are now conducted via telemedicine. Her work extends beyond the clinic; she developed the "Wake Up and Learn" program, a school-based sleep education and screening initiative, and actively uses social media to educate the public on health. This deep commitment to accessible, data-driven healthcare aligns perfectly with NanoMosaic's mission.

Her extensive experience as a principal investigator and advisor for numerous pharmaceutical companies - including Takeda, Eisai, and Harmony Biosciences - provides her with a crucial understanding of the drug development pipeline's bottlenecks and needs. She is uniquely positioned to bridge the gap between diagnostic innovation and pharmaceutical application.

"I am incredibly excited to embrace my new role as Chair of the Clinical Advisory Board for NanoMosaic," Dr. Morse stated in the official announcement. "I envision NanoMosaic as a truly transformative force - a U.S.-based, cost-effective, and efficient platform that will elevate the standard of care in neurology and beyond. Its potential for precise diagnostics and innovative biomarker assays positions it to make a profound impact on population health while supporting the individualized patient journey."

The Technology Driving the Shift: Inside the Tessie™ Platform

At the heart of NanoMosaic's strategy is its Tessie™ platform, a system designed to deliver the power of a central laboratory in a portable, plug-and-play format. The technology's competitive advantage stems from a unique combination of features that address long-standing limitations in biomarker detection.

The platform boasts femtogram-per-milliliter sensitivity, a level of precision capable of detecting ultra-low-abundance biomarkers that are often the earliest signs of disease. Critically, Tessie™ can achieve this sensitivity directly from crude biological samples like plasma, saliva, tears, or cerebrospinal fluid without requiring complex and time-consuming purification steps. This simplifies the workflow, reduces the potential for errors, and makes testing more accessible outside of specialized labs.

Powered by proprietary "MosaicNeedles™" - nanoscale biosensors - the platform is also multi-omic, capable of detecting both proteins and nucleic acids in a single run. Perhaps its most significant technical differentiator is its 7-log dynamic range, allowing it to simultaneously measure biomarkers present at vastly different concentrations. While many existing technologies are restricted to a much narrower range, Tessie™ can provide a more comprehensive biological snapshot in one test.

With results delivered in as little as 7.5 seconds per sample within a high-throughput run, the platform is built for speed and scale. This is not merely a theoretical promise; NanoMosaic has already placed instruments at leading institutions like Massachusetts General Hospital, where researchers are actively developing and validating a diagnostic test for post-operative delirium. The company has also signaled that blood-based pTau detection for Alzheimer's disease is on its near-term roadmap, a key battleground in the fight against neurodegenerative disease.

Reshaping Pharmaceutical R&D and Clinical Trials

The appointment of Dr. Morse and the deployment of the Tessie™ platform are aimed squarely at the multi-billion-dollar challenge of neurological drug development. The companion diagnostics (CDx) market, projected to exceed $22 billion by 2032, is rapidly expanding into neurology to address the immense need for precision medicine. Tessie™ is engineered to create the very companion diagnostics that can de-risk this process.

By enabling pharmaceutical companies to identify which patients are most likely to respond to a new therapy early in a clinical trial, the platform can dramatically improve trial efficiency. This patient stratification helps design smaller, more powerful studies, reduces the risk of late-stage failures, and lowers the immense financial burden of drug development. Furthermore, it reduces the patient burden by ensuring participants are enrolled in trials where they are most likely to benefit.

The platform's portability and ease of use make it an ideal tool for the burgeoning field of decentralized clinical trials (DCTs). DCTs, which bring trial activities to a patient's home or local clinic, improve access for diverse and remote populations but create logistical hurdles for sample collection and analysis. A portable system that provides rapid, lab-grade results from a simple blood or saliva sample can eliminate many of these challenges, accelerating patient recruitment and enabling real-time data collection that was previously impossible. This aligns with the FDA's regulatory framework, which encourages the co-development of drugs and their corresponding companion diagnostics to ensure therapies are used safely and effectively from the moment they reach the market.

The Push for "Brain Health" and Population Screening

Beyond optimizing pharmaceutical R&D, NanoMosaic's vision extends to fundamentally changing how "Brain Health" is managed at a population level. The ability to perform highly sensitive, non-invasive biomarker tests at the point of need opens the door to proactive health screening and early disease detection on a massive scale.

For devastating conditions like Alzheimer's and Parkinson's disease, which often have a long subclinical phase before symptoms become apparent, early detection is critical. A fast, affordable, and accessible test could become a routine part of primary care, allowing for interventions long before irreversible neurological damage occurs. This represents a paradigm shift from reactive treatment of symptoms to proactive management of brain health.

This broader mission is backed by significant investor confidence. The company has raised over $44 million, with a $40.75 million Series A round led by prominent life sciences investor RA Capital Management, signaling strong belief in its technology and strategy.

"Anne's leadership reinforces our mission to move precision medicine closer to patients," said John Boyce, Chairman and Co-Founder of NanoMosaic. "By enabling real-time, ultra-sensitive diagnostics outside of traditional lab settings, we can streamline how therapies reach patients, accelerate care, and alleviate suffering by getting the right treatments to the right people faster."

With a seasoned clinical visionary, a groundbreaking diagnostic platform, and strong financial backing, NanoMosaic is positioning itself not just as a technology provider, but as a central player in the next chapter of neurological medicine. The integration of its technology into mainstream clinical workflows could finally provide the tools needed to turn the tide against some of the most complex and challenging diseases facing humanity.